Oral Vaccine Focused Penny Stock Vaxart Is 'Uniquely Positioned', Analyst Sees Almost 83% Upside
Portfolio Pulse from Vandana Singh
Oppenheimer initiated coverage on Vaxart Inc. (NASDAQ:VXRT) with an Outperform rating and a price target of $4, citing the company's unique position in developing oral vaccines for COVID-19 and norovirus. The analyst sees an 83% upside potential, supported by a $453M BARDA-funded project and the unmet need for a norovirus vaccine.
August 15, 2024 | 5:57 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Oppenheimer initiated coverage on Vaxart Inc. with an Outperform rating and a $4 price target, highlighting the company's potential in oral vaccines for COVID-19 and norovirus. The analyst sees an 83% upside potential.
The initiation of coverage with an Outperform rating and a significant price target by Oppenheimer is likely to boost investor confidence and drive short-term price appreciation. The focus on unmet needs in the norovirus vaccine market and the support from a large BARDA-funded project further strengthen the bullish outlook.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100